InspireMD (NSPR) CCO auto-sells shares to cover RSU tax obligations

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

InspireMD, Inc.’s Chief Commercial Officer Shane Thomas Gleason reported a series of open-market sales of common stock primarily to cover tax withholding on vested restricted stock. The latest transaction on May 19, 2026 involved selling 22,778 shares at a weighted average price of $1.01 per share.

The filing shows a total of 85,295 shares sold across 14 transactions since early 2025, all described as required sales under an automatic sales instruction letter effecting a sell-to-cover election. Following the most recent sale, Gleason directly holds 1,053,882 shares of InspireMD common stock.

Insights

Routine, pre-arranged tax-related insider sales with large remaining stake.

The transactions by InspireMD’s Chief Commercial Officer are all coded as open-market sales of common stock, totaling 85,295 shares since 2025. Footnotes state these sales were required to cover tax withholding on restricted stock vesting under an automatic sales instruction letter adopted on November 25, 2024.

Because these are sell-to-cover transactions rather than discretionary trades, they carry weaker informational value about management’s view of the stock. After the most recent sale of 22,778 shares at a weighted average of $1.01, the officer still directly owns 1,053,882 shares, indicating a substantial continuing equity position.

Insider Trade Summary

Net Seller: 85,295 shares ($189,594)

Net Sell 14 txns

Insider Gleason Shane Thomas

Role Chief Commercial Officer

Sold 85,295 shs ($190K)

Type	Security	Shares	Price	Value
Sale	Common Stock	22,778	$1.01	$23K
Sale	Common Stock	2,941	$1.59	$5K
Sale	Common Stock	7,186	$2.51	$18K
Sale	Common Stock	3,760	$2.51	$9K
Sale	Common Stock	1,572	$2.51	$4K
Sale	Common Stock	2,482	$2.51	$6K
Sale	Common Stock	10,000	$3.65	$37K
Sale	Common Stock	5,132	$2.46	$13K
Sale	Common Stock	7,073	$2.51	$18K
Sale	Common Stock	9,923	$2.55	$25K
Sale	Common Stock	2,454	$2.51	$6K
Sale	Common Stock	3,660	$2.46	$9K
Sale	Common Stock	2,476	$2.61	$6K
Sale	Common Stock	3,858	$2.71	$10K

Holdings After Transaction: Common Stock — 1,053,882 shares (Direct, null)

Footnotes (1)

The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.00 to $1.04. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Key Figures

Latest shares sold: 22,778 shares Latest sale price: $1.01 per share Total shares sold in filing: 85,295 shares +2 more

5 metrics

Latest shares sold 22,778 shares Common stock sale on May 19, 2026

Latest sale price $1.01 per share Weighted average price on May 19, 2026

Total shares sold in filing 85,295 shares Aggregate sales across 14 transactions since 2025

Shares held after latest sale 1,053,882 shares Direct ownership following May 19, 2026 transaction

Prior notable sale 10,000 shares at $3.65 Common stock sale on February 25, 2025

Key Terms

restricted stock grants, sell-to-cover election, weighted average price, automatic sales instruction letter

4 terms

restricted stock grants financial

"in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter"

sell-to-cover election financial

"automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election"

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

automatic sales instruction letter financial

"pursuant to an automatic sales instruction letter adopted by the reporting person"

Form 4 Insider Transactions: What Each Field Means →

05/21/2026 - 05:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gleason Shane Thomas

(Last)

(First)

(Middle)

C/O INSPIREMD, INC.

6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)

MIAMI

FLORIDA

33126

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/27/2025		S		3,858⁽¹⁾	D	$2.71	1,135,319	D
Common Stock	01/28/2025		S		2,476⁽¹⁾	D	$2.61	1,132,843	D
Common Stock	01/29/2025		S		3,660⁽¹⁾	D	$2.46	1,129,183	D
Common Stock	01/30/2025		S		2,454⁽¹⁾	D	$2.51	1,126,729	D
Common Stock	01/31/2025		S		9,923⁽¹⁾	D	$2.55	1,116,806	D
Common Stock	02/03/2025		S		7,073⁽¹⁾	D	$2.51	1,109,733	D
Common Stock	02/04/2025		S		5,132⁽¹⁾	D	$2.46	1,104,601	D
Common Stock	02/25/2025		S		10,000⁽¹⁾	D	$3.65	1,094,601	D
Common Stock	05/23/2025		S		2,482⁽¹⁾	D	$2.51	1,092,119	D
Common Stock	05/27/2025		S		1,572⁽¹⁾	D	$2.51	1,090,547	D
Common Stock	05/29/2025		S		3,760⁽¹⁾	D	$2.51	1,086,787	D
Common Stock	05/30/2025		S		7,186⁽¹⁾	D	$2.51	1,079,601	D
Common Stock	02/02/2026		S		2,941⁽¹⁾	D	$1.59	1,076,660	D
Common Stock	05/19/2026		S		22,778⁽¹⁾	D	$1.01⁽²⁾	1,053,882	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person.

2. The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.00 to $1.04. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

	/s/ Michael Lawless, Attorney-in-Fact for Shane Gleason	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did InspireMD (NSPR) report for its Chief Commercial Officer?

InspireMD disclosed that Chief Commercial Officer Shane Thomas Gleason sold company common stock in multiple transactions totaling 85,295 shares. These sales span from January 2025 through May 19, 2026 and are all reported as open-market transactions in the Form 4 filing.

How many InspireMD (NSPR) shares did the CCO sell in the latest transaction and at what price?

In the most recent trade on May 19, 2026, the Chief Commercial Officer sold 22,778 shares of InspireMD common stock. The shares were sold at a weighted average price of $1.01, with individual trades ranging from $1.00 to $1.04 per share.

Why were InspireMD (NSPR) shares sold by the Chief Commercial Officer according to the Form 4?

The Form 4 states the sales represent shares required to be sold to cover tax withholding obligations tied to vesting restricted stock grants. They were executed under an automatic sales instruction letter reflecting a sell-to-cover election, and are described as non-discretionary trades.

How many InspireMD (NSPR) shares does the Chief Commercial Officer still own after these sales?

After the May 19, 2026 transaction, the Chief Commercial Officer directly holds 1,053,882 shares of InspireMD common stock. This post-transaction figure is disclosed in the Form 4 for the latest sale and reflects his remaining direct equity stake in the company.

Over what period do the InspireMD (NSPR) insider sales in this Form 4 occur?

The Form 4 aggregates 14 sale transactions in InspireMD common stock, beginning January 27, 2025 and continuing through May 19, 2026. All are reported as open-market sales and together account for 85,295 shares sold by the Chief Commercial Officer.

Are the InspireMD (NSPR) insider sales described as discretionary trades?

No. The footnotes explain that the sales were required to cover tax withholding obligations from restricted stock vesting under an automatic sales instruction letter. The filing explicitly notes these sales do not represent discretionary trades by the reporting person.